Loading...
XSTO
VITR
Market cap1.31bUSD
Oct 09, Last price  
95.60SEK
1D
3.88%
1Q
11.46%
Jan 2017
24.42%
IPO
1,889.10%
Name

Vitrolife AB

Chart & performance

D1W1MN
XSTO:VITR chart
P/E
—
P/S
3.76
EPS
—
Div yield, %
1.14%
Shrs. gr., 5y
4.52%
Rev. gr., 5y
22.53%
Revenues
3.44b
-4.68%
171,264,000188,939,000225,141,000274,626,000297,565,000356,115,000362,020,000452,738,000510,512,000722,370,000856,106,0001,046,217,0001,151,348,0001,480,132,0001,245,572,0001,680,804,0003,234,000,0003,512,000,0003,609,000,0003,440,000,000
Net income
-5.01b
L
15,199,00036,057,00029,995,00034,114,00029,182,00030,360,000333,772,00056,274,000109,109,000182,845,000190,368,000263,640,000309,697,000382,785,000286,845,000341,000,000394,000,000-3,851,000,000513,000,000-5,013,000,000
CFO
635m
-29.99%
23,784,00021,285,00042,793,00041,478,00048,399,00039,460,00059,930,000106,127,000145,666,000193,526,000181,262,000312,189,000349,435,000413,333,000356,448,000384,306,000636,000,000757,000,000907,000,000635,000,000
Dividend
May 06, 20261.1 SEK/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Vitrolife AB (publ) is a medical technology company specializing in the development, production, and global sale of products for assisted reproduction. Their comprehensive offering includes a variety of essential tools for fertility treatments, such as oocyte retrieval needles, sperm processing solutions, specialized in vitro fertilization media and oils, and micromanipulation pipettes. The company also provides general labware, incubators, cryopreservation products, and systems for preimplantation genetic testing. Furthermore, Vitrolife delivers advanced equipment, including the EmbryoScope and Primo Vision time-lapse systems, along with dedicated dishes and evaluation software for these platforms. Their technology portfolio extends to Octax laser and imaging systems, as well as environmental monitoring solutions like log and guard systems and wireless sensors. With its headquarters located in Gothenburg, Sweden, Vitrolife maintains a significant international presence, operating across Europe, the Middle East, and Africa; Asia; Japan and the Pacific; and both North and South America. Founded in 1994, the company was initially known as Scandinavian IVF Science before officially changing its name to Vitrolife AB (publ) in 1998.

Key people

Claus Bisgaard
Vice President Technology
Mark Larman
Chief Scientific Officer · since 2017
Lars Holmqvist
Independent Director · since 2018
Independent Director · since 2013
IPO date
Jun 26, 2001
Employees
1,102
Domiciled in
SE
Incorporated in
SE
Headquarters & legal address
Box 9080
Göteborg, O 400 92
SE
Address
Box 9080
Goteborg, O 400 92
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT